Prostatype Genomics

Prostatype Genomics Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Prostatype Genomics (PROGEN.ST) as of Nov 5, 2026 is 53.48 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 108.91 % — a change of -50.89% (lower).

Cash Conversion

53.48 %

YoY

-50.89%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Prostatype Genomics is 2025 53.48 % . Cash Conversion Rate (OCF/Net Income) of Prostatype Genomics was 2024 108.91 % . It decreases by -50.89% lower compared to the previous year.

The Prostatype Genomics Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2017
61.28 SEK
Jan 1, 2018
112.69 SEK
Jan 1, 2020
84.51 SEK
Jan 1, 2021
102.87 SEK
Jan 1, 2022
95.21 SEK
Jan 1, 2023
70.32 SEK
Jan 1, 2024
108.91 SEK
Jan 1, 2025
53.48 SEK
The Prostatype Genomics Cash Conversion history
YEARCash ConversionYoY
53.48 %-50.89%
108.91 %+54.87%
70.32 %-26.14%
95.21 %-7.45%
102.87 %+21.72%
84.51 %-25.01%
112.69 %+83.91%
61.28 %-69.80%
202.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Cash Conversion Rate (OCF/Net Income) of Prostatype Genomics is 53.48 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Prostatype Genomics changed from 108.91 % to 53.48 %, representing a -50.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Prostatype Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Prostatype Genomics

All Key Metrics — Prostatype Genomics